Sangamo analyst commentary at Wells FargoSangamo price target raised to $34 from $24 at Wells Fargo. Wells Fargo analyst Jim Birchenough raised his price target for Sangamo Therapeutics to $34 from $24 following this morning's clinical update on the company's gene therapy, gene editing and cell therapy pipeline. The stock in morning trading is up 35%, or $3.35, to $12.88. The update was better than expected, particularly for hemophilia gene therapy and beta thalassemia ex vivo gene editing, Birchenough tells investors in a research note. The analyst is "encouraged" by Sangamo's progress against the higher technical hurdle of in vivo genome editing. He believes direct evidence of genome editing, "strong" fetal hemoglobin response and early signs of transfusion independence bode well for ultimate success and should translate into improved likelihood of success in the larger opportunity of sickle cell disease. The analyst reiterates an Outperform rating on Sangamo Therapeutics.Read more at: (source)https://thefly.com/landingPage...Tiger's Take: $SGMO UP 30%+ TODAY!! On our trading list, a small biotech with great potential. Keep in mind though it is also in the "high risk/high reward" category. Good news in preclinical data. Still very early, but potential is really high. $SGMO, Sangamo Therapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or comments.